Results 171 to 180 of about 14,742 (206)
Some of the next articles are maybe not open access.
Frontotemporal lobar degeneration
2015Main imaging findings: Patterns of atrophy (CT/MRI) or functional alterations (PET/SPECT) supporting clinical diagnosis of FTLD variants: bvFTD: bilateral, often asymmetrical involvement of frontal and anterior temporal structures; nfvPPA: left posterior fronto-insular damage; svPPA: anterior temporal lobe involvement, usually left ...
Filippi M, Agosta F
openaire +3 more sources
Apathy and impulsivity in frontotemporal lobar degeneration syndromes
Brain, 2017 There has been considerable progress in the clinical, pathological and genetic fractionation of frontotemporal lobar degeneration syndromes in recent years, driving the development of novel diagnostic criteria.
P Simon Jones +2 more
exaly +3 more sources
From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers
International Review of Psychiatry, 2013Frontotemporal dementia (FTD) is an increasingly recognized cause of dementia. This review discusses the different FTD clinical syndromes and frontotemporal lobar degeneration (FTLD) pathological correlates as well as new genetic and proteomic findings that have added to our understanding of FTLD pathogenesis.
Chadwick M, Hales, William T, Hu
openaire +2 more sources
Analysis of optineurin in frontotemporal lobar degeneration
Neurobiology of Aging, 2012 Frontotemporal lobar degeneration (FTLD) can occur jointly with amyotrophic lateral sclerosis (ALS), and these 2 conditions share a genetic risk factor on chromosome 9. It has been reported that mutations in optineurin (OPTN) can cause ALS. Therefore, we
Sara Rollinson +2 more
exaly +2 more sources
Epidemiology of Frontotemporal Lobar Degeneration
Dementia and Geriatric Cognitive Disorders, 2004A few epidemiologic studies have dealt with the prevalence of frontotemporal lobar degeneration (FTLD), including Pick’s disease. The aim of this study was to review the epidemiologic studies of FTLD in western countries and to compare them with those in Japan.
Manabu, Ikeda +2 more
openaire +2 more sources
Initial Complaints in Frontotemporal Lobar Degeneration
Dementia and Geriatric Cognitive Disorders, 2004<i>Aims:</i> Frontotemporal lobar degeneration (FTLD) is probably underrecognized. The goal of this study was to investigate initial complaints of both patients and their caregivers at first specialist referral. Also, we tried to assess whether misrecognition of symptoms contributed to diagnostic delay.
Pijnenburg, Yolande A.L. +3 more
openaire +3 more sources
Molecular Pathways of Frontotemporal Lobar Degeneration
Annual Review of Neuroscience, 2010Frontotemporal lobar degeneration (FTLD) is a neurodegenerative condition that predominantly affects behavior, social awareness, and language. It is characterized by extensive heterogeneity at the clinical, pathological, and genetic levels. Recognition of these levels of heterogeneity is important for proper disease management.
Sleegers, K. +2 more
openaire +3 more sources
Frontotemporal Lobar Degeneration
Gerontology, 2001Frontotemporal lobar degeneration is the second most common form of cortical dementia in the presenium after Alzheimer’s disease. Clinically, based on consensus guidelines, three distinct disease entities can be distinguished: frontotemporal dementia, semantic dementia and progressive nonfluent aphasia. Dementia of frontal type and motor neuron disease
M. Tolnay, A. Probst
openaire +3 more sources
Frontotemporal Lobar Degeneration
2017Frontotemporal dementia (FTD) is an uncommon but important form of degenerative disease characterized by clinical syndromes that result from degeneration of the frontal and temporal lobes. FTD is divided based on clinical presentation into behavioral variant FTD (bvFTD), semantic dementia, and progressive nonfluent/agrammatic aphasia.
Jonathan Graff-Radford, Keith A. Josephs
openaire +1 more source
Fluid Biomarkers of Frontotemporal Lobar Degeneration
2021A timely diagnosis of frontotemporal degeneration (FTD) is frequently challenging due to the heterogeneous symptomatology and poor phenotype-pathological correlation. Fluid biomarkers that reflect FTD pathophysiology could be instrumental in both clinical practice and pharmaceutical trials.
van der Ende, Emma, van Swieten, J.C.
openaire +3 more sources